REGULATORY REQUIREMENTS FOR SUBMITTING HIV RESISTANCE DATA
Sponsors are required to use the following sample format for submitting HIV resistance data to FDA.
One dataset combines patient data, endpoint data, genotypic data, and phenotypic data. There are a number of ways datasets can be subdivided (i.e., by clinical study, baseline isolates, or virologic failure isolates) and this should be discussed with the division before submission.
For each study, we recommend constructing datasets as SAS transport files containing the following information:
• One record (row) per patient per isolate (e.g., baseline, failure, and other time points).
• Data in columns (with suggested column headings shown below)4 on all isolates.
• Genotypic data should be provided on the corresponding record for each patient isolate for baseline isolates of all patients in treatment-experienced studies and the endpoint isolates of virologic failures and discontinuations in all studies.5 In treatment-naïve studies, a baseline sample should be collected and stored from all patients for future phenotypic and genotypic analysis of virologic failures.
• Phenotypic data should be provided on the corresponding record for each patient isolate for baseline isolates and the endpoint isolates of virologic failures and discontinuations.5 In treatment-experienced studies, it is recommended that baseline phenotypic data be obtained for all patients.
The specific criteria for defining virologic failures should be discussed with the division and may include multiple primary and secondary protocol endpoints. The endpoints for clinical virologic and resistance outcome analyses should be consistent.
Information to Include with Suggested Column Headings4
I. Patient Data:
• Patient identification number (ID number should be unique for all studies)
• Isolate (e.g., baseline, week 24, week 48, discontinuation. Multiple isolates should be numbered.)
• Date of isolate
• Study day (number of days since the patient started the study product)
• Previous therapeutic products where available
• Treatment group
• Censored for analysis (yes or no)
II. Endpoint Data:
• HIV RNA (copies/mL) at baseline (viral loads less than LLOQ should be listed as “ • HIV RNA (copies/mL) at predefined time points (e.g., week 24 and week 48), one column for each time point including baseline (i.e., the viral load throughout the course of the study is provided for each sample)
• HIV RNA (copies/mL) at other times (e.g., loss of virologic response or discontinuation because of adverse event)
• Endpoint assessment (e.g., mean log change in viral load from baseline)
• Other endpoint assessments (e.g., DAVG)
• Indication of data were censored for reasons other than virologic failure (e.g., discontinuation because of adverse event)
• Outcome (i.e., responder, virologic failure, discontinuation while suppressed, discontinuation before achieving viral suppression)
• Reason for discontinuation (i.e., adverse event, pregnancy) or failure (i.e., never suppressed, rebound)
• HIV RNA (copies/ml) from additional time points can be included
III. Genotypic Data:
Clade
• Genotype for the RT, protease, and gp160 (for products targeting entry only), one amino acid per column with the WT amino acid as column heading. Changes from WT standard sequence indicated (i.e., blanks indicate no change).
• Column with total number of PI mutations in patient isolate (for baseline and endpoint isolates). The specific mutations to include should be discussed with the division in advance.
• Column with total number of NRTI mutations in patient isolate (for baseline and endpoint isolates). The specific mutations to include should be discussed with the division in advance.
• Column with total number of NNRTI mutations in patient isolate (for baseline and endpoint isolates). The specific mutations to include should be discussed with the division in advance.
Example (Table A highlights how genotype information can be displayed, but does not include all column headings previously suggested.)
IV. Protease Cleavage Sites (for protease inhibitors only):
• NC/p1 Gag cleavage sites: show amino acid and position of cleavage site of WT in column headings (as above for genotype) and indicate amino acid change if mutant
• p1/p6 Gag cleavage sites: show amino acid and position of cleavage site of WT in column headings (as above for genotype) and indicate amino acid change if mutant
V. Phenotypic Data:
1. Information on the investigational product
• Baseline EC50 value for investigational product
• Baseline EC50 value of reference strain for investigational product
• Fold resistant change of baseline EC50 value compared to EC50 value of reference strain of investigational product
• EC50 value at time of endpoint assessment or failure for investigational product
• Fold change in EC50 value at time of endpoint assessment or failure compared to reference strain for investigational product
• Fold change in EC50 value at time of endpoint assessment or failure compared to baseline for investigational product
• Replication capacity (if available)
2. Information on approved and other investigational anti-HIV products (if available) in the same class
• Fold change in EC50 value of baseline compared to reference strain for each of the approved and other investigational anti-HIV products (if available)
• Fold change in EC50 value at time of endpoint assessment or failure compared to reference strain for each of the approved and other investigational anti-HIV products (if available)
• Fold change in EC50 value at time of endpoint assessment or failure compared to baseline for each of the approved and other investigational anti-HIV products (if available)
3. Information on approved and other investigational products (if available) outside the investigational product’s class with same target protein (e.g., NRTIs and NNRTIs)
• Fold change in EC50 value of baseline compared to reference strain for approved and other investigational products (if available) outside the investigational product’s class
• Fold change in EC50 value at time of endpoint assessment or failure compared to reference strain for each of the approved and other investigational products (if available) outside the investigational product’s class
• Fold change in EC50 value at time of endpoint assessment or failure compared to baseline for each of the approved and other investigational products (if available) outside the investigational product’s class
4. Information on other antiretroviral products in the regimen
• Fold change in EC50 value of baseline compared to reference strain for other antiretroviral products in the regimen, one column per product
• Fold change in EC50 value at time of endpoint assessment or failure compared to reference strain for other antiretroviral products in the regimen, one column per product
• Fold change in EC50 value at time of endpoint assessment or failure compared to baseline for other antiretroviral products in the regimen, one column per product
Example (Table B highlights how phenotype information can be displayed, but does not include all column headings previously suggested.)
VI. Co-Receptor Usage (for all agents targeting co-receptors):
• Co-receptor usage of baseline isolates. Indicate R5, X4, D for dual-tropic, M for mixed-tropic, or D/M if the assay cannot distinguish between dual or mixed, in a column.
• Baseline R5 tropism assay value (e.g., RLUs).
• Baseline X4 tropism assay value (e.g., RLUs).
Co-receptor usage of virologic failures and end-of-study isolates (on therapy). Indicate R5, X4, D for dual-tropic, M for mixed-tropic, or D/M if the assay cannot distinguish between dual or mixed, in a column.
• R5 tropism assay value at failure or end of study (e.g., RLUs).
• X4 tropism assay value at failure or end of study (e.g., RLUs).
VII. Therapeutic Drug Monitoring Data (when available):
• Patient’s Cmin
• Serum adjusted IQ (inhibitory quotient = Cmin/serum adjusted EC50 value)
IV. NONCLINICAL STUDIES
A. Mechanism of Action
B. Antiviral Activity in Cell Culture
C. Cytotoxicity and Therapeutic Indexes
D. Protein Binding
E. Selection of Drug-Resistant HIV-1 Variants in Cell Culture
1. Genotype
2. Phenotype
F. Cross-Resistance
G. Characterization of Genotypic and Phenotypic Assays
1. Genotypic Assays
2. Phenotypic Assays
V. CLINICAL STUDIES: USE OF RESISTANCE TESTING IN CLINICAL PHASES OF DRUG DEVELOPMENT
A. General Considerations
B. Data Collection
C. Methods and Types of Analyses
1. Baseline Genotype and Virologic Response
2. Development of HIV Mutations
3. Baseline Phenotype and Virologic Response
4. Genotypic and Phenotypic Correlations: Changes in Susceptibility from Baseline
5. Cross-Resistance
6. Additional Analyses
D. Other Considerations
1. Role for Supporting Initial Activity and Dose-Finding Studies
2. Data Collection from Dose-Finding Trials
3. Use of Resistance Data to Establish an Indication
4. Use of Resistance Data for Study Enrollment Criteria, Background Regimen Selection, and Stratification Factors
5. Nonclade B Subtypes
E. Monitoring during Phase 4
REGULATORY REQUIREMENTS FOR SUBMITTING HIV RESISTANCE DATA
SUMMARY
There is much more information on HIV virus new findings available on this blog.
Here are given details about symptoms of AIDS , all new symptoms of AIDS and HIV virus infection are updated.
------------------------------------------------------------------------------------------------------------
This website provideds complete information about hiv virus , hiv infection , early hiv symptoms , hiv treatment,hiv test and hiv testing centers, aids symptoms, symptoms of hiv immideately after infection.
------------------------------------------------------------------------------------------------------------
Following are the most read topic on this website you should find them on blog archive of this website
Stem cell treatment for AIDS
AIDS symptoms
SYMPTOMS OF HIV
HIV infection symptoms
Latest treatment for AIDS
How anti retroviral medicines are developed
How Chemotherapeutic drugs are developed to treat HIV virus infection
New drug developments against HIV Virus AIDS
Vaccines research for HIV AIDS Why it is difficult to develop a vaccine against HIV
Mother to child prevention of HIV virus infection.
hiv virus infection prevention and education bloggers
Information about HIV Virus AIDS symptoms
Source:
Drug Resistance Assay and Antiretroviral drug development guidance--->
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071173.pdf
Last updated: 28-Oct-2010
Sponsors are required to use the following sample format for submitting HIV resistance data to FDA.
One dataset combines patient data, endpoint data, genotypic data, and phenotypic data. There are a number of ways datasets can be subdivided (i.e., by clinical study, baseline isolates, or virologic failure isolates) and this should be discussed with the division before submission.
For each study, we recommend constructing datasets as SAS transport files containing the following information:
• One record (row) per patient per isolate (e.g., baseline, failure, and other time points).
• Data in columns (with suggested column headings shown below)4 on all isolates.
• Genotypic data should be provided on the corresponding record for each patient isolate for baseline isolates of all patients in treatment-experienced studies and the endpoint isolates of virologic failures and discontinuations in all studies.5 In treatment-naïve studies, a baseline sample should be collected and stored from all patients for future phenotypic and genotypic analysis of virologic failures.
• Phenotypic data should be provided on the corresponding record for each patient isolate for baseline isolates and the endpoint isolates of virologic failures and discontinuations.5 In treatment-experienced studies, it is recommended that baseline phenotypic data be obtained for all patients.
The specific criteria for defining virologic failures should be discussed with the division and may include multiple primary and secondary protocol endpoints. The endpoints for clinical virologic and resistance outcome analyses should be consistent.
Information to Include with Suggested Column Headings4
I. Patient Data:
• Patient identification number (ID number should be unique for all studies)
• Isolate (e.g., baseline, week 24, week 48, discontinuation. Multiple isolates should be numbered.)
• Date of isolate
• Study day (number of days since the patient started the study product)
• Previous therapeutic products where available
• Treatment group
• Censored for analysis (yes or no)
II. Endpoint Data:
• HIV RNA (copies/mL) at baseline (viral loads less than LLOQ should be listed as “
• HIV RNA (copies/mL) at other times (e.g., loss of virologic response or discontinuation because of adverse event)
• Endpoint assessment (e.g., mean log change in viral load from baseline)
• Other endpoint assessments (e.g., DAVG)
• Indication of data were censored for reasons other than virologic failure (e.g., discontinuation because of adverse event)
• Outcome (i.e., responder, virologic failure, discontinuation while suppressed, discontinuation before achieving viral suppression)
• Reason for discontinuation (i.e., adverse event, pregnancy) or failure (i.e., never suppressed, rebound)
• HIV RNA (copies/ml) from additional time points can be included
III. Genotypic Data:
Clade
• Genotype for the RT, protease, and gp160 (for products targeting entry only), one amino acid per column with the WT amino acid as column heading. Changes from WT standard sequence indicated (i.e., blanks indicate no change).
• Column with total number of PI mutations in patient isolate (for baseline and endpoint isolates). The specific mutations to include should be discussed with the division in advance.
• Column with total number of NRTI mutations in patient isolate (for baseline and endpoint isolates). The specific mutations to include should be discussed with the division in advance.
• Column with total number of NNRTI mutations in patient isolate (for baseline and endpoint isolates). The specific mutations to include should be discussed with the division in advance.
Example (Table A highlights how genotype information can be displayed, but does not include all column headings previously suggested.)
IV. Protease Cleavage Sites (for protease inhibitors only):
• NC/p1 Gag cleavage sites: show amino acid and position of cleavage site of WT in column headings (as above for genotype) and indicate amino acid change if mutant
• p1/p6 Gag cleavage sites: show amino acid and position of cleavage site of WT in column headings (as above for genotype) and indicate amino acid change if mutant
V. Phenotypic Data:
1. Information on the investigational product
• Baseline EC50 value for investigational product
• Baseline EC50 value of reference strain for investigational product
• Fold resistant change of baseline EC50 value compared to EC50 value of reference strain of investigational product
• EC50 value at time of endpoint assessment or failure for investigational product
• Fold change in EC50 value at time of endpoint assessment or failure compared to reference strain for investigational product
• Fold change in EC50 value at time of endpoint assessment or failure compared to baseline for investigational product
• Replication capacity (if available)
2. Information on approved and other investigational anti-HIV products (if available) in the same class
• Fold change in EC50 value of baseline compared to reference strain for each of the approved and other investigational anti-HIV products (if available)
• Fold change in EC50 value at time of endpoint assessment or failure compared to reference strain for each of the approved and other investigational anti-HIV products (if available)
• Fold change in EC50 value at time of endpoint assessment or failure compared to baseline for each of the approved and other investigational anti-HIV products (if available)
3. Information on approved and other investigational products (if available) outside the investigational product’s class with same target protein (e.g., NRTIs and NNRTIs)
• Fold change in EC50 value of baseline compared to reference strain for approved and other investigational products (if available) outside the investigational product’s class
• Fold change in EC50 value at time of endpoint assessment or failure compared to reference strain for each of the approved and other investigational products (if available) outside the investigational product’s class
• Fold change in EC50 value at time of endpoint assessment or failure compared to baseline for each of the approved and other investigational products (if available) outside the investigational product’s class
4. Information on other antiretroviral products in the regimen
• Fold change in EC50 value of baseline compared to reference strain for other antiretroviral products in the regimen, one column per product
• Fold change in EC50 value at time of endpoint assessment or failure compared to reference strain for other antiretroviral products in the regimen, one column per product
• Fold change in EC50 value at time of endpoint assessment or failure compared to baseline for other antiretroviral products in the regimen, one column per product
Example (Table B highlights how phenotype information can be displayed, but does not include all column headings previously suggested.)
VI. Co-Receptor Usage (for all agents targeting co-receptors):
• Co-receptor usage of baseline isolates. Indicate R5, X4, D for dual-tropic, M for mixed-tropic, or D/M if the assay cannot distinguish between dual or mixed, in a column.
• Baseline R5 tropism assay value (e.g., RLUs).
• Baseline X4 tropism assay value (e.g., RLUs).
Co-receptor usage of virologic failures and end-of-study isolates (on therapy). Indicate R5, X4, D for dual-tropic, M for mixed-tropic, or D/M if the assay cannot distinguish between dual or mixed, in a column.
• R5 tropism assay value at failure or end of study (e.g., RLUs).
• X4 tropism assay value at failure or end of study (e.g., RLUs).
VII. Therapeutic Drug Monitoring Data (when available):
• Patient’s Cmin
• Serum adjusted IQ (inhibitory quotient = Cmin/serum adjusted EC50 value)
IV. NONCLINICAL STUDIES
A. Mechanism of Action
B. Antiviral Activity in Cell Culture
C. Cytotoxicity and Therapeutic Indexes
D. Protein Binding
E. Selection of Drug-Resistant HIV-1 Variants in Cell Culture
1. Genotype
2. Phenotype
F. Cross-Resistance
G. Characterization of Genotypic and Phenotypic Assays
1. Genotypic Assays
2. Phenotypic Assays
V. CLINICAL STUDIES: USE OF RESISTANCE TESTING IN CLINICAL PHASES OF DRUG DEVELOPMENT
A. General Considerations
B. Data Collection
C. Methods and Types of Analyses
1. Baseline Genotype and Virologic Response
2. Development of HIV Mutations
3. Baseline Phenotype and Virologic Response
4. Genotypic and Phenotypic Correlations: Changes in Susceptibility from Baseline
5. Cross-Resistance
6. Additional Analyses
D. Other Considerations
1. Role for Supporting Initial Activity and Dose-Finding Studies
2. Data Collection from Dose-Finding Trials
3. Use of Resistance Data to Establish an Indication
4. Use of Resistance Data for Study Enrollment Criteria, Background Regimen Selection, and Stratification Factors
5. Nonclade B Subtypes
E. Monitoring during Phase 4
REGULATORY REQUIREMENTS FOR SUBMITTING HIV RESISTANCE DATA
SUMMARY
There is much more information on HIV virus new findings available on this blog.
Here are given details about symptoms of AIDS , all new symptoms of AIDS and HIV virus infection are updated.
------------------------------------------------------------------------------------------------------------
This website provideds complete information about hiv virus , hiv infection , early hiv symptoms , hiv treatment,hiv test and hiv testing centers, aids symptoms, symptoms of hiv immideately after infection.
------------------------------------------------------------------------------------------------------------
Following are the most read topic on this website you should find them on blog archive of this website
Stem cell treatment for AIDS
AIDS symptoms
SYMPTOMS OF HIV
HIV infection symptoms
Latest treatment for AIDS
How anti retroviral medicines are developed
How Chemotherapeutic drugs are developed to treat HIV virus infection
New drug developments against HIV Virus AIDS
Vaccines research for HIV AIDS Why it is difficult to develop a vaccine against HIV
Mother to child prevention of HIV virus infection.
hiv virus infection prevention and education bloggers
Information about HIV Virus AIDS symptoms
Source:
Drug Resistance Assay and Antiretroviral drug development guidance--->
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071173.pdf
Last updated: 28-Oct-2010
No comments:
Post a Comment